NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Interesting paper online (published May 31, 2022)
Roel Verhaak, Fred Varn et al. compare DNA & RNA genomic tumor data from 304 patients with diffuse glioma to I.D. the most frequent changes taking place at recurrence, and provide a basis for new therapeutic strategies.

Link paper” Glioma progression is shaped by genetic evolution and microenvironment interactions.” https://www.sciencedirect.com/science/article/pii/S0092867422005360?dgcid=coauthor#bib25

Link PR May 31: “PREDICTING GLIOMA CHANGES BEFORE RECURRENCE”
By Mark Wanner
https://www.jax.org/news-and-insights/2022/may/predicting-glioma-changes-before-recurrence

In the GLASS cohort, the transcriptomic subtype of IDH wild-type tumors was found to shift between original diagnosis and recurrence in nearly half of IDH-wild-type tumor patients. Further investigation showed that these changes resulted from the commonly used chemoradiation treatment and associated changes in the types of non-cancer cells found in the tumor microenvironment. In contrast, most IDH-mutant tumors stayed proneural at both time points. The team summarized these changes into three distinct recurrence-specific phenotypes (collection of traits)—neuronal, mesenchymal, and proliferative—based on the cellular, genetic, and histological features that emerge at recurrence. Future studies are being developed to understand how these acquired characteristics can be exploited for making treatment more effective.

Link Fred Varn : https://mobile.twitter.com/fsvarn